Published in Blood Weekly, June 16th, 2005
Additional data presented at the meeting demonstrate that NuvaRing provides better cycle control than an oral contraceptive and that it is well tolerated in extended regimens of use, beyond the standard 3-week cycle. The data were presented for the first time at the American College of Obstetricians and Gynecologists (ACOG) Annual Meeting in San Francisco, California.
The body weight data were derived from a secondary analysis of the efficacy...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.